Services

Here at flow, we provide various research services for academic collaborators and private partners. Our services include research studies, drug screening, development of new reporter lines, zebrafish embryos and adults, and training in zebrafish husbandry, research and molecular approaches. 

Drug safety profile

  • Mortality assay. Survival rate dose-response. Drug concentration for 50% mortality rate (LC50). Drug treatment for 48-72h in 3-5 days post-fertilization larvae.

  • Neurotoxicity. Seizure liability assay, locomotor assay. Seizure-like swimming behaviors.

  • Cardiotoxicity assay. Heat rate, arrhythmia, cardiac arrest. Cardiotoxicity using kdrl-GFP (previously called flk-GFP) line.

  • Hepatotoxicity assay. Drug-induced liver injury. Quantification of liver size and yolk sac retention.

Disease models

  • Epilepsy assays. Behavioral assessments in zebrafish models of epilepsy (gabra1-/-).

  • Nociception assays. Behavioral response to pain stimuli (formalin, AITC, heat).

  • Respiratory assays. Changes in respiratory behaviors (respiratory depression) in response to drug exposure.

  • Zebrafish models of Parkinson's Disease:

 - Neurotoxicant zebrafish models of PD. Loss of dopamine neurons using 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) or MPP+ combined with locomotor assessment in larval zebrafish.

 - Loss of dopamine neurons with MPTP combined with the reporter line for dopamine transporter dat Tg(dat:EGFP) also called Tg(slc6a3:EGFP)9. 
- Knockdown of genes involved in Parkinson’s Diseases in larval zebrafish.
- Transient knockdowns of PD-associated genes (Dj-1, pink1, and Parkin) using morpholino antisense oligonucleotides and locomotor assessments.

  • Zebrafish models of cardiovascular diseases. Vascular endothelial growth factor receptor kdr-like (kdrl-GFP) reporter line. 

Gene editing in zebrafish

Need more details? Contact us

We are here to assist. Contact us by phone, email or via our social media channels.

  • Targeted mutagenesis of genes of interest using CRISPR/Cas9 technology. Rapid and robust biallelic mutations performed in microinjected single-cell embryos allowing phenotype-driven mutagenesis screens or permanent mutants. 

  • Transient knockdown using morpholino antisense oligonucleotides. Short-term knockdown in gene expression up to 4 days post-fertilization.